TW200640498A - Suspending vehicles and pharmaceutical suspensions for drug dosage forms - Google Patents

Suspending vehicles and pharmaceutical suspensions for drug dosage forms

Info

Publication number
TW200640498A
TW200640498A TW095103806A TW95103806A TW200640498A TW 200640498 A TW200640498 A TW 200640498A TW 095103806 A TW095103806 A TW 095103806A TW 95103806 A TW95103806 A TW 95103806A TW 200640498 A TW200640498 A TW 200640498A
Authority
TW
Taiwan
Prior art keywords
suspensions
vehicles
dosage forms
drug dosage
pharmaceutical suspensions
Prior art date
Application number
TW095103806A
Other languages
English (en)
Inventor
Catherine Manya Rohloff
Stephen Andrew Berry
Eric William Weeks
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of TW200640498A publication Critical patent/TW200640498A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
TW095103806A 2005-02-03 2006-02-03 Suspending vehicles and pharmaceutical suspensions for drug dosage forms TW200640498A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65045405P 2005-02-03 2005-02-03
US11/342,445 US20060216242A1 (en) 2005-02-03 2006-01-30 Suspending vehicles and pharmaceutical suspensions for drug dosage forms

Publications (1)

Publication Number Publication Date
TW200640498A true TW200640498A (en) 2006-12-01

Family

ID=36658698

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095103806A TW200640498A (en) 2005-02-03 2006-02-03 Suspending vehicles and pharmaceutical suspensions for drug dosage forms

Country Status (4)

Country Link
US (1) US20060216242A1 (zh)
AR (1) AR055031A1 (zh)
TW (1) TW200640498A (zh)
WO (1) WO2006083799A2 (zh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
CA2489325C (en) * 2002-06-17 2010-08-10 Alza Corporation Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2006521897A (ja) * 2003-03-31 2006-09-28 アルザ・コーポレーション 内部圧力を放散する手段を備える浸透ポンプ
KR20050120767A (ko) * 2003-03-31 2005-12-23 알자 코포레이션 삼투성 전달 시스템 및 삼투성 전달 시스템의 기동 시간감소 방법
BRPI0416094A (pt) * 2003-10-31 2007-01-02 Alza Corp bomba osmótica com plugue de membrana de inicialização rápida, de auto-retenção
KR20060121890A (ko) * 2003-11-06 2006-11-29 알자 코포레이션 이식형 삼투 펌프와 함께 사용하기 위한 모듈식 흡수율감소기
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20060263433A1 (en) * 2005-02-03 2006-11-23 Ayer Rupal A Suspension formulation of interferon
US7959938B2 (en) * 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8586556B2 (en) * 2006-11-03 2013-11-19 Allergan, Inc. Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CN104013569A (zh) * 2008-10-15 2014-09-03 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用
WO2010146536A1 (en) * 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
WO2011007327A2 (en) * 2009-07-16 2011-01-20 Koninklijke Philips Electronics N.V. Suspension for therapeutic use and device for delivering said suspension
LT2462246T (lt) * 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
CN101701065B (zh) * 2009-10-14 2011-08-10 南京威尔化工有限公司 高纯度聚山梨酯-80的合成方法
US9271939B2 (en) 2010-03-15 2016-03-01 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
IE20100174A1 (en) * 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102352032B (zh) * 2011-07-21 2013-03-06 南京威尔化工有限公司 通过起始原料分别醚化再混合后与油酸酯化制备高纯度聚山梨酯80的方法
SG11201407512VA (en) 2012-05-18 2014-12-30 Genentech Inc High-concentration monoclonal antibody formulations
CN106456704A (zh) 2014-04-16 2017-02-22 Veyx-药物有限公司 兽药组合物和其应用
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス，インコーポレイティド インプラントの設置及び撤去システム
CL2016000217A1 (es) * 2016-01-27 2016-07-01 Farmacologia En Aquacultura Veterinaria Fav S A Nueva composición veterinaria inyectable para la sincronización del desove en peces
EP3452003A4 (en) * 2016-05-05 2019-06-26 Triastek, Inc. PHARMACEUTICAL FORM WITH CONTROLLED RELEASE
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556905A (en) * 1994-03-30 1996-09-17 Reilly Industries, Inc. Physically-modified degradable thermoplastic compositions
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6132420A (en) * 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6156331A (en) * 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) * 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
WO1997027840A1 (en) * 1996-02-02 1997-08-07 Alza Corporation Sustained delivery of an active agent using an implantable system
AU739469B2 (en) * 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
ES2378675T3 (es) * 1997-12-30 2012-04-16 Intarcia Therapeutics, Inc Sistema de suministro de un agente beneficioso con una membrana obturadora
MXPA04004665A (es) * 2001-11-14 2004-09-10 Alza Corp Composiciones de deposito inyectable y uso de los mismos.
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
KR20060002922A (ko) * 2003-03-31 2006-01-09 알자 코포레이션 비수성 단일 상 비히클 및 이러한 비히클을 이용한 제형
RS53890B1 (en) * 2004-11-10 2015-08-31 Tolmar Therapeutics, Inc. STABILIZED POLYMER DELIVERY SYSTEM

Also Published As

Publication number Publication date
US20060216242A1 (en) 2006-09-28
WO2006083799A2 (en) 2006-08-10
AR055031A1 (es) 2007-08-01
WO2006083799A3 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
TW200640498A (en) Suspending vehicles and pharmaceutical suspensions for drug dosage forms
BRPI0414000B8 (pt) composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
MXPA05008909A (es) Formulacion intranasal de rotigotina.
NZ597757A (en) Aqueous insulin preparations containing methionine
TW200744667A (en) Foamable suspension gel
MX2009011247A (es) Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
RS52367B (en) GLATIRAMER ACETATE FORMULATION FORMATED VOLUMES AND APPLICATION PROCEDURES
WO2011031855A3 (en) Implantable device for controlled drug delivery
CL2009002073A1 (es) Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares.
MXPA04008906A (es) Composicion que tiene propiedades gelificantes para el suministro prolongado de sustancias bioactivas.
DE60321386D1 (de) Pharmazeutische zubereitung zur modifizierten freisetzung
IS8430A (is) Lyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn
WO2012040623A3 (en) Nanostructured gels capable of controlled release of encapsulated agents
HK1079448A1 (en) Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
WO2006039336A3 (en) Conveniently implantable sustained release drug compositions
PT1834635E (pt) Sistemas estáveis de nanocápsula para a administração de moléculas activas
HK1118011A1 (zh) 透明質酸的抗腫瘤生物結合物或以化學接合方法間接地取得的衍生物，以及其製藥用途
WO2006124681A3 (en) Oral drug delivery system and methods of use thereof
WO2008060365A3 (en) A self-gelling tunable drug delivery system
WO2006023497A3 (en) Intranasal delivery of antipsychotic drugs
IS8428A (is) Innrennslislyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn
WO2006085217A3 (en) Solid adsorbates of hydrophobic drugs
EA200100802A1 (ru) Применение тианептина при приготовлении лекарственных средств, предназначенных для лечения нейродегенеративных патологий
GB0522474D0 (en) A pharmaceutical formulation
WO2004071386A3 (en) Compositions comprising microcapsules containing magnetic nanoparticles and biologically active molecules, their preparation and use